Obeticholic acid for hepatitis B patients with fatty liver
Part of Digestive system, Infections clinical trials.
This study tests a medication called obeticholic acid to see if it improves liver fat and blood flow in people who have chronic hepatitis B and fatty liver. If you qualify, you may receive this treatment and be monitored with ultrasound and liver scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have chronic hepatitis B and be on treatment for it.
- You must have fatty liver, confirmed by a special scan showing a CAP value greater than 238 dB/m.
- You cannot have other types of hepatitis (like hepatitis C).
- You cannot have liver cancer, blood clots in the liver vein (portal vein thrombosis), or other specific liver diseases.
- You must not drink alcohol heavily or take medications that can cause fatty liver, and your body mass index (BMI) must be below 35.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ACT500 for people who have both fatty liver disease and chronic hepatitis B. The goal is to see if it is safe and how well it works. It might help reduce fat in the liver and improve liver health.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
This study tests a new medicine called Hepalatide for people with chronic hepatitis D, a serious liver infection. It aims to see if the drug can reduce the virus and improve liver health. You may be eligible if you have both hepatitis B and D and are on stable hepatitis B treatment.
This trial tests whether an oral medication called ursodeoxycholic acid can help lower bilirubin levels in people with acute viral hepatitis. Lower bilirubin may help reduce jaundice and improve liver recovery.
Hear when a new Steatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.